This article is more than 5 years old. Information may no longer be current.
Greater extent of edema associated with worse visual acuity
Click Here to Manage Email Alerts
BOSTON — Patients with diabetic macular edema who experienced a greater extent of edema at 52 weeks post-ranibizumab treatment experienced worse anatomic response compared with patients with less extent of macular edema, according to a poster presented at the American Society of Retina Specialists meeting.
Pravin U. Dugel, MD, and colleagues presented the findings of a post hoc analysis of 367 eyes from the Lucentis (ranibizumab, Genentech) treatment arms in the Diabetic Retinopathy Clinical Research Center Network Protocol I study. Eyes were organized into quartiles depending on the extent of their macular edema at 52 weeks. Ninety-two patients were included in quartile 1 (4 m average extent of edema), 92 were included in quartile 2 (18 m), 92 in quartile three (47 m) and 91 in quartile 4 (129 m).
After adjusting for key factors, researchers found patients in quartile 4 were estimated to gain 6.9 fewer letters and those in quartile 3 gained 5.3 fewer letters at week 52. At week 156, quartile 3 gained 7 fewer letters and quartile 4 gained 9.3 fewer letters when compared to quartile 1.
Quartile 1 also showed significantly higher odds of a 10-letter or greater improvement at week 52 and week 156 than quartiles 3 and 4. – by Robert Linnehan
Reference:
Dugel PU, et al. The association between average extent of edema in diabetic macular edema at 52 weeks and long-term vision outcomes: A post hoc analysis of Protocol I. Presented at: American Society of Retina Specialists 35th Annual Meeting, Aug. 11-15, 2017; Boston.
Disclosure: Dugel reports consultancy fees from Abbott, AMO, Aerpio, Alcon, Alimera Sciences, Allergan, Acucela, Avalanche Biotechnologies, Clearside Biomedical, Genentech, LusBioScience, OD-OS, Ophthotech, Opthea, ORA, Regeneron Pharmaceuticals, Roche, Stealth BioTherapeutics and ThromboGenics. He reports a personal financial interest in Alimera Sciences, Aerpio, Neurotetch and Ophthotech.